Urokinase is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, chest embolism within 6-12 hours of coronary embolism and myocardial infarction, acute cerebral embolism less than 3-6 hours, retinal artery embolism and other peripheral arterial embolization symptoms of severe iliac-femoral vein Thrombosis. It is also used to prevent thrombosis after artificial heart valve surgery, and to maintain the vascular access and the patency of the thoracic cavity and pericardial drainage tube. The efficacy of thrombolysis requires maintenance of subsequent heparin anticoagulation.
Urokinase is an enzyme thrombolytic agent that activates the conversion of plasminogen to plasmin in the body, thereby hydrolyzing fibrin to dissolve the newly formed thrombus. For acute myocardial infarction, acute cerebral thrombosis and cerebral embolism, limb arteriovenous thrombosis, central retinal arteriovenous thrombosis and other fresh thromboembolic diseases. This product has no obvious effect on old thrombosis. Urokinase is also suitable for the treatment of cerebral thrombosis, peripheral vascular embolism, central retinal vascular embolism, acute myocardial infarction and other fresh thromboembolic diseases, as well as thrombosis in renal transplantation, plastic surgery, etc., have a good effect.
Urokinase is mainly used for thrombolytic therapy of thromboembolic diseases
